ReviewGut pathogens2024
The influence of Akkermansia muciniphila on intestinal barrier function.
Review in Gut pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 110 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
110 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- The Gut Microbiota in Addiction Biology: A Systematic Review of Substance-Induced Dysbiosis and Gut-Brain Axis Alterations.Medical sciences (Basel, Switzerland) · 2026Pooled it
- The impact of very-low-calorie ketogenic diets on gut microbiota in individuals with obesity: a systematic review and meta-analysis.Gut microbes · 2025Pooled it
- The role ofFrontiers in medicine · 2025Pooled it
- Angiotensin converting enzyme inhibitors and angiotensin receptor blockers impact on the gut microbiome: a systematic review.Frontiers in endocrinology · 2025Pooled it
- The impact ofFrontiers in cellular and infection microbiology · 2025Pooled it
- Probiotic improves respiratory and gastrointestinal health, immune homeostasis, and gut microbiota composition in infants: a randomized controlled trial.Frontiers in nutrition · 2026Trial
- Trial
- Supplementation with resveratrol modified gut microbiota improving insulin sensitivity and lipid metabolism in subjects with obesity and insulin resistance.European journal of nutrition · 2025Trial
- Targeted Microbial Shifts and Metabolite Profiles Were Associated with Clinical Response to an Anti-Inflammatory Diet in Osteoarthritis.Nutrients · 2025Trial
- Rethinking probiotics: breaking theGut microbes · 2026Review
- Review
- Gut‑liver‑kidney axis: A systems biology framework for understanding and treating chronic kidney disease (Review).International journal of molecular medicine · 2026Review
- Akkermansia muciniphila : A next-generation gut probiotic supporting neurorepair and functional recovery.Neural regeneration research · 2026Article
- Decoding Akkermansia muciniphila Effector Biology: From Microbial Molecules to Host Outcomes.MicrobiologyOpen · 2026Review
- The gut microbiota mediates the antidepressant effects of imipramine: Evidence from fecal microbiota transplantation and prebiotic inulin intervention.Psychopharmacology · 2026Article
- Microbiota and immune-related adverse events in cancer immunotherapy.Nature reviews. Cancer · 2026Review
- Periodontitis during pregnancy: The effect on the gut microbiome and intestinal inflammation.Journal of periodontology · 2026Article
- Review
- Deep Eutectic Solvent-Based Extraction Optimization, Structural Characterization, and Alleviating Effects ofFoods (Basel, Switzerland) · 2026Article
- Gut Bacteria: A Beneficial Symbiosis or a Hidden Threat? Investigating the Dual Role of Bacteria in Gastrointestinal Diseases.Current microbiology · 2026Review
50 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Intestinal barriers play a crucial role in human physiology, both in homeostatic and pathological conditions. Disruption of the intestinal barrier is a significant factor in the pathogenesis of gastrointestinal inflammatory diseases, such as inflammatory bowel disease. The profound influence of the gut microbiota on intestinal diseases has sparked considerable interest in manipulating it through dietary interventions, probiotics, and fecal microbiota transplantation as potential approaches to enhance the integrity of the intestinal barrier. Numerous studies have underscored the protective effects of specific microbiota and their associated metabolites. In recent years, an increasing body of research has demonstrated that Akkermansia muciniphila (A. muciniphila, Am) plays a beneficial role in various diseases, including diabetes, obesity, aging, cancer, and metabolic syndrome. It is gaining popularity as a regulator that influences the intestinal flora and intestinal barrier and is recognized as a 'new generation of probiotics'. Consequently, it may represent a potential target and promising therapy option for intestinal diseases. This article systematically summarizes the role of Am in the gut. Specifically, we carefully discuss key scientific issues that need resolution in the future regarding beneficial bacteria represented by Am, which may provide insights for the application of drugs targeting Am in clinical treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.